The Value of a Deep Learning Image Reconstruction Algorithm on Low Dose Triphasic-enhanced Renal CT

Author:

Ding Xiaobo1,Li Jing1,Qiu Xiang1,Hu Xiaohan1,Sun Pengfei1,Zhang Shuai2,Li Wenhuan2,Remer Erick M3,Wang Yanbo1,Zhang Huimao1

Affiliation:

1. First Hospital of Jilin University

2. GE Healthcare

3. Cleveland Clinic

Abstract

Abstract

Background: While deep learning image reconstruction(DLIR) has been applied successfully in thoracic, abdominal, and vascular examinations, its application in low-dose renal CT protocols has not been previously explored. Purpose: To explore the value of DLIR in reducing radiation dose and improving image quality in contrast-enhanced renal CT compared with the adaptive statistical iterative reconstruction Veo(ASIR-V). Material and Methods: Methods: 129 renal disease patients underwent unenhanced and triphasic-enhanced CT scans, utilizing a standard 120 kVp dose for parenchymal-phase scans and a lower 100 kVp dose for corticomedullary-phase scans. Images in both phases were reconstructed with high-strength DLIR(DLIR-H), medium-strength DLIR(DLIR-M) and ASIR-V level 50%(ASIR-V-50%) for comparison. CT values and standard deviations were measured and compared for various tissues in both phases, and two radiologists assessed image quality using a 5-point Likert scale in seven aspects. Results: A total of 118 patients were included, with corticomedullary-phase radiation dose reduced by over 15% compared to parenchymal-phase (CTDIvol: 6.57±2.13mGy vs. 7.75±2.63mGy). DLIR-M and DLIR-H exhibited significantly lower image noise in both phases compared to ASIR-V-50% (p<0.001). Corticomedullary-phase DLIR-M and DLIR-H images reduced subcutaneous-adipose tissue noise by 15% and 40% compared to parenchymal-phase ASIR-V-50%. Subjectively, DLIR-H (4.16±0.62) and DLIR-M (3.76±0.68) using 100 kVp outperformed ASIR-V-50% (3.42±0.52) at 120 kVp (p<0.001). Conclusion: DLIR-H and DLIR-M significantly reduce image noise and generate images with better image quality and diagnostic confidence with a 15% dose reduction than ASIR-V-50%. Clinical Trial Number 2023-278, First Hospital of Jilin University, Changchun, China.

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3